Literature DB >> 20924360

Pulmonary hypertension with left-sided heart disease.

Marco Guazzi1, Ross Arena.   

Abstract

Pulmonary hypertension (PH) with left-sided heart disease is defined, according to the latest Venice classification, as a Group 2 PH, which includes left-sided ventricular or atrial disease, and left-sided valvular diseases. These conditions are all associated with increased left ventricular filling pressure. Although PH with left-sided heart disease is a common entity, and long-term follow-up trials have provided firm recognition that development of left-sided PH carries a poor outcome, available data on incidence, pathophysiology, and therapy are sparse. Mitral stenosis was reported as the most frequent cause of PH several decades ago, but PH with left-sided heart disease is now usually caused by systemic hypertension and ischemic heart disease. In patients with these conditions, PH develops as a consequence of impaired left ventricular relaxation and distensibility. Chronic sustained elevation of cardiogenic blood pressure in pulmonary capillaries leads to a cascade of untoward retrograde anatomical and functional effects that represent specific targets for therapeutic intervention. The pathophysiological and clinical importance of the hemodynamic consequences of left-sided heart disease, starting with lung capillary injury and leading to right ventricular overload and failure, are discussed in this Review, focusing on PH as an evolving contributor to heart failure that may be amenable to novel interventions.

Entities:  

Mesh:

Year:  2010        PMID: 20924360     DOI: 10.1038/nrcardio.2010.144

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  124 in total

Review 1.  Clinical practice. Diastolic heart failure.

Authors:  Gerard P Aurigemma; William H Gaasch
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

2.  Prognostic importance of various echocardiographic right ventricular functional parameters in patients with symptomatic heart failure.

Authors:  Jaroslav Meluzin; Lenka Spinarová; Petr Hude; Jan Krejcí; Vladimír Kincl; Roman Panovský; Ladislav Dusek
Journal:  J Am Soc Echocardiogr       Date:  2005-05       Impact factor: 5.251

3.  Ultrastructural appearances of pulmonary capillaries at high transmural pressures.

Authors:  K Tsukimoto; O Mathieu-Costello; R Prediletto; A R Elliott; J B West
Journal:  J Appl Physiol (1985)       Date:  1991-08

4.  Electron microscopic studies on the alveolar-capillary barrier in the patients of chronic pulmonary edema.

Authors:  Y S Lee
Journal:  Jpn Circ J       Date:  1979-10

5.  Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).

Authors:  Thomas F Lüscher; Frank Enseleit; Richard Pacher; Veselin Mitrovic; Matthias R Schulze; Roland Willenbrock; Rainer Dietz; Valentin Rousson; David Hürlimann; Sebastian Philipp; Thomas Notter; Georg Noll; Frank Ruschitzka
Journal:  Circulation       Date:  2002-11-19       Impact factor: 29.690

6.  The pathogenesis of acute pulmonary edema associated with hypertension.

Authors:  S K Gandhi; J C Powers; A M Nomeir; K Fowle; D W Kitzman; K M Rankin; W C Little
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

7.  Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.

Authors:  Milton Packer; John McMurray; Barry M Massie; Abraham Caspi; Vincent Charlon; Alain Cohen-Solal; Wolfgang Kiowski; William Kostuk; Henry Krum; Barry Levine; Paolo Rizzon; Jordi Soler; Karl Swedberg; Susan Anderson; David L Demets
Journal:  J Card Fail       Date:  2005-02       Impact factor: 5.712

8.  Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure.

Authors:  M Hülsmann; B Stanek; B Frey; B Sturm; D Putz; T Kos; R Berger; W Woloszczuk; D Putz; T Kos; R Berger; W Woloszczuk; G Maurer; R Pacher
Journal:  J Am Coll Cardiol       Date:  1998-11-15       Impact factor: 24.094

9.  Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone.

Authors:  Gregory D Lewis; Ravi V Shah; Paul P Pappagianopolas; David M Systrom; Marc J Semigran
Journal:  Circ Heart Fail       Date:  2008-11       Impact factor: 8.790

10.  PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.

Authors:  Ryan J Tedford; Anna R Hemnes; Stuart D Russell; Ilan S Wittstein; Mobusher Mahmud; Ari L Zaiman; Stephen C Mathai; David R Thiemann; Paul M Hassoun; Reda E Girgis; Jonathan B Orens; Ashish S Shah; David Yuh; John V Conte; Hunter C Champion
Journal:  Circ Heart Fail       Date:  2008-11       Impact factor: 8.790

View more
  33 in total

Review 1.  Pulmonary Hypertension with Valvular Heart Disease: When to Treat the Valve Disease and When to Treat the Pulmonary Hypertension.

Authors:  Christophe Martinez; Toshimitsu Tsugu; Tadafumi Sugimoto; Patrizio Lancellotti
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

2.  Catching a Disease: A Molecular Trap as a Therapy for Pulmonary Arterial Hypertension.

Authors:  Beth L Roman; Cynthia St Hilaire
Journal:  Am J Respir Crit Care Med       Date:  2016-11-01       Impact factor: 21.405

3.  Pulmonary arterial hypertension in the elderly: Clinical perspectives.

Authors:  Nicholas Rothbard; Abhinav Agrawal; Conrad Fischer; Arunabh Talwar; Sonu Sahni
Journal:  Cardiol J       Date:  2018-08-29       Impact factor: 2.737

Review 4.  Assessment and treatment of right ventricular failure.

Authors:  Marc A Simon
Journal:  Nat Rev Cardiol       Date:  2013-02-12       Impact factor: 32.419

Review 5.  Pulmonary Hypertension in Heart Failure Patients: Pathophysiology and Prognostic Implications.

Authors:  Marco Guazzi; Valentina Labate
Journal:  Curr Heart Fail Rep       Date:  2016-12

Review 6.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.

Authors:  Johannes-Peter Stasch; Pál Pacher; Oleg V Evgenov
Journal:  Circulation       Date:  2011-05-24       Impact factor: 29.690

7.  Swine model of chronic postcapillary pulmonary hypertension with right ventricular remodeling: long-term characterization by cardiac catheterization, magnetic resonance, and pathology.

Authors:  Daniel Pereda; Ana García-Alvarez; Damián Sánchez-Quintana; Mario Nuño; Leticia Fernández-Friera; Rodrigo Fernández-Jiménez; José Manuel García-Ruíz; Elena Sandoval; Jaume Aguero; Manuel Castellá; Roger J Hajjar; Valentín Fuster; Borja Ibáñez
Journal:  J Cardiovasc Transl Res       Date:  2014-04-26       Impact factor: 4.132

8.  Management of severe pulmonary hypertension in patients undergoing mitral valve surgery.

Authors:  Carlos D Davila; Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-06

9.  Impact of net atrioventricular compliance on clinical outcome in mitral stenosis.

Authors:  Maria Carmo P Nunes; Judy Hung; Marcia M Barbosa; William A Esteves; Vinicius T Carvalho; Lucas Lodi-Junqueira; Cirilo P Fonseca Neto; Timothy C Tan; Robert A Levine
Journal:  Circ Cardiovasc Imaging       Date:  2013-10-04       Impact factor: 7.792

10.  Pulmonary hypertension secondary to left-heart failure involves peroxynitrite-induced downregulation of PTEN in the lung.

Authors:  Yazhini Ravi; Karuppaiyah Selvendiran; Shan K Naidu; Sarath Meduru; Lucas A Citro; Balázs Bognár; Mahmood Khan; Tamás Kálai; Kálmán Hideg; Periannan Kuppusamy; Chittoor B Sai-Sudhakar
Journal:  Hypertension       Date:  2013-01-21       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.